(Q38391811)

2 September 2017

1 reference

title

Emerging immunotherapies for bladder cancer (English)

1 reference

2 September 2017

1 reference

3

Jane Trepel

1 reference

2 September 2017

Joseph W Kim

1

1 reference

PubMed ID

25811346

2 September 2017

Yusuke Tomita

series ordinal

2

1 reference

PubMed ID

25811346

2 September 2017

Andrea B Apolo

series ordinal

4

1 reference

2 September 2017

1 May 2015

1 reference

Current Opinion in Oncology

2 September 2017

1 reference

2 September 2017

27

1 reference

2 September 2017

191-200

1 reference

2 September 2017

3

1 reference

Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF

2 September 2017

1 reference

12 December 2020

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

12 December 2020

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

1 reference

12 December 2020

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.

1 reference

12 December 2020

Poxviral vectors for cancer immunotherapy

1 reference

12 December 2020

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer

1 reference

12 December 2020

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

12 December 2020

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

1 reference

12 December 2020

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

1 reference

12 December 2020

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

PD-1 and its ligands in tolerance and immunity

1 reference

12 December 2020

The geriatrics and genetics behind bladder cancer

1 reference

12 December 2020

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody

1 reference

12 December 2020

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

1 reference

12 December 2020

Microenvironmental regulation of tumor progression and metastasis

1 reference

12 December 2020

The contrasting role of B7-H3.

1 reference

12 December 2020

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

12 December 2020

Exploiting the curative potential of adoptive T-cell therapy for cancer

1 reference

12 December 2020

Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer

1 reference

12 December 2020

Cancer-testis antigen expression in bladder cancer.

1 reference

12 December 2020

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

12 December 2020

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 December 2020

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

1 reference

12 December 2020

Global cancer statistics

1 reference

12 December 2020

Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.

1 reference

12 December 2020

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

1 reference

12 December 2020

Immunogenic cell death in cancer therapy

1 reference

12 December 2020

Cancer immunotherapy highlights from the 2014 ASCO Meeting

1 reference

12 December 2020

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

12 December 2020

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

1 reference

12 December 2020

MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

1 reference

12 December 2020

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

1 reference

12 December 2020

Therapeutic cancer vaccines: past, present, and future

1 reference

12 December 2020

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

1 reference

12 December 2020

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

1 reference

12 December 2020

Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.

1 reference

12 December 2020

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

1 reference

12 December 2020

Significance of MUC1 in bladder cancer

1 reference

12 December 2020

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

1 reference

12 December 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

1 reference

12 December 2020

Agonistic CD40 antibodies and cancer therapy

1 reference

12 December 2020

The secret ally: immunostimulation by anticancer drugs

1 reference

12 December 2020

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).

1 reference

12 December 2020

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer

1 reference

12 December 2020

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

1 reference

12 December 2020

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

12 December 2020

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

1 reference

12 December 2020

The PD-1 pathway in tolerance and autoimmunity

1 reference

12 December 2020

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

12 December 2020

OX40 is a potent immune-stimulating target in late-stage cancer patients

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

Oncology meets immunology: the cancer-immunity cycle

1 reference

12 December 2020

Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity

1 reference

12 December 2020

Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?

1 reference

12 December 2020

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

12 December 2020

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

1 reference

12 December 2020

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

1 reference

12 December 2020

Signaling through OX40 enhances antitumor immunity

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

12 December 2020

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

1 reference

12 December 2020

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

1 reference

12 December 2020

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

1 reference

12 December 2020

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival

1 reference

12 December 2020

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

1 reference

12 December 2020

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

1 reference

12 December 2020

Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

1 reference

12 December 2020

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

1 reference

12 December 2020

Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance.

1 reference

12 December 2020

10.1097/CCO.0000000000000177

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25811346